Growth hormone therapy for Prader-Willi syndrome: A critical appraisal

Journal of Pediatric Endocrinology and Metabolism

Volumn 17, Issue SUPPL. 4, 2004, Pages 1297-1306

  Allen, David B ^a   Carrel, Aaron L ^a  

^a University of Wisconsin Children's Hospital   (United States)

Author keywords

Growth hormone; Obesity; Prader Willi syndrome

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE; SOMATOMEDIN C;

ARTICLE; BEHAVIOR DISORDER; BODY COMPOSITION; BODY HEIGHT; BRAIN PSEUDOTUMOR; CARDIOPULMONARY INSUFFICIENCY; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DRUG FATALITY; ENERGY EXPENDITURE; FEMALE; GLUCOSE INTOLERANCE; GROWTH RATE; HUMAN; HYPOGONADISM; HYPOTHALAMUS DISEASE; INSULIN RESISTANCE; INTRACRANIAL HYPERTENSION; LEAN BODY WEIGHT; LONG TERM CARE; MALE; MUSCLE HYPOTONIA; MUSCLE MASS; MUSCLE WEAKNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOPOROSIS; PATHOGENESIS; PHYSICAL CAPACITY; PRADER WILLI SYNDROME; RESPIRATORY TRACT DISEASE; SCOLIOSIS;

CHILD; HUMAN GROWTH HORMONE; HUMANS; PRADER-WILLI SYNDROME;

EID: 4644245259     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Prader A, Labhart A, Willi H. Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchismus und Oligophrenie. Schweiz Med Wochenschr 1956; 86: 1260-1261.
2. Butler MG, Thompson T. Prader-Willi syndrome: clinical and genetic findings. Endocrinologist 2000; 10 (Suppl 1): 3S-16S.
3. Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term growth hormone therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 2002; 87: 1581-1585.
4. Ritzen EM, Bolme P, Hall K. Endocrine physiology and therapy in Prader-Willi syndrome. In: Cassidy SB, ed. Prader-Willi Syndrome and Other 15q Deletion Disorders. NATO ASI Series, Volume H61. Berlin: Springer-Verlag, 1992; 153-169.
5. Brambilla P, Bosio L, Manzoni P. Peculiar body composition in patients with Prader-Labhart-Willi syndrome. Am J Clin Nutr 1997; 65: 1369-1374.
6. Bekx MT, Carrel AL, Schriver TC, Li Z, Allen DB. Decreased energy expenditure is caused by abnormal body composition in infants with Prader Willi syndrome. J Pediatr; in press.
7. Lindgren AC, Ritzen EM. Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group. Acta Paediatr 1999; 88 (Suppl 433): 109-111.
8. Carrel AL, Myers SE, Whitman BY, Allen DB. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study. J Pediatr 1999; 134: 215-221.
9. Davies PS. Growth hormone therapy in Prader-Willi syndrome. Int J Obes 2001; 25: 2-7.
10. Angulo M, Castro-Magana M, Mazur B, Canas JA, Vitollo PM, Sarrantonio M. Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome. J Pediatr Endocrinol Metab 1996; 9: 393-400.
11. Lindgren AC, Hagenas L, Muller J, Blichfeldt S, Rosenborg M, Brismar T, Ritzen EM. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably. Acta Paediatr 1998; 87: 28-31.
12. Eiholzer U, l'Allemand D. Growth hormone normalizes height, prediction of final height, hand length in children with Prader-Willi syndrome after 4 years of therapy. Horm Res 2000; 53: 185-192.
13. Obata K, Sakazume S, Yoshino A, Murakami N, Sakuta R. Effects of 5 years GH treatment in patients with Prader-Willi syndrome. J Pediatr Endocrinol Metab 2003; 16: 155-162.
14. Raben M, Hollenberg CH. Effect of growth hormone on plasma fatty acids. J Clin Invest 1959; 38: 484-488.
15. Dieguez C, Casanueva FF. Influence of metabolic substrates and obesity on growth hormone secretion. Trends Endocrinol Metab 1995; 6: 55-59.
16. Eiholzer U, Bachmann S, l'Allemand D. Is there growth hormone deficiency in Prader-Willi syndrome? Six arguments to support the presence of hypothalamic growth hormone deficiency in PWS. Horm Res 2000; 53 (Suppl 3): 44-52.
17. Haqq AM, Farooqi S, O'Rahilly S, Stadler DS, Rosenfeld RG, Pratt KL, LaFranchi SH, Purnell JQ. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab 2003; 88: 174-178.
18. Guo SS, Chumlea WC, Roche AF, Siervogel RM. Age-and maturity-related changes in body composition during adolescence into adulthood: the Fels Longitudinal Study. Int J Obes Relat Metab Disord 1997; 21: 1167-1175.
19. Carrel AL, Myers SE, Whitman BY, Allen DB. Sustained benefits of growth hormone in children with Prader-Willi syndrome are dose-dependent. J Pediatr Endocrinol Metab 2001; 14: 1096-1105.
20. Haqq AM, Stadler DD, Jackson RH, Rosenfeld RG, Purnell JQ, LaFranchi SH. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J Clin Endocrinol Metab 2003; 88: 2206-2212.
21. Hakonarson H, Moskovitz J, Daigle KL, Cassidy SB, Cloutier MM. Pulmonary function abnormalities in Prader-Willi syndrome. J Pediatr 1995; 126: 565-570.
22. Menendez A. Abnormal ventilatory responses in patients with Prader-Willi syndrome. Eur J Pediatr 1999; 158: 941-942.
23. 2 response, ventilation, and central inspiratory drive in children with Prader-Willi syndrome. Eur J Pediatr 1999; 158: 936-940.
24. Whitman B, Myers S, Carrel AL, Allen DB. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study. Pediatrics 2002; 109: e35.
25. Hoybye C, Frystyk J, Thoren M. The growth hormone-insulin-like-growth factor axis in adult patients with Prader Willi syndrome. Growth Horm IGF Res 2003; 13: 269-274.
26. Hoybye C, Hilding A, Jacobsson H, Thoren M. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome. Clin Endocrinol 2003; 58: 653-661.
27. Myers SE, Carrel AL, Whitman BY, Allen DB. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, drid growth in Prader-Willi syndrome. J Pediatr 2000; 137: 42-49.
28. Butler MG, Hovis CL, Angulo MA. Photoanthropometric study of craniofacial traits in individuals with Prader-Willi syndrome on short-term growth hormone therapy. Clin Genet 1998; 53: 268-275.
29. l'Allemand D, Eiholzer U, Schlumpf M, Torresani T, Girard J. Carbohydrate metabolism is not impaired after 3 years of growth hormone therapy in children with Prader-Willi syndrome. Horm Res 2003; 59: 239-248.
30. Lippe B. Pfizer statement: Prader-Willi syndrome and death. May, 2003.
31. Whittington JE, Holland AJ, Webb T, Butler J, Clarke D, Boer H. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J Med Genet 2001; 38: 792-798.